Qiagen (QGEN) Appoints Stephen Rusckowski as Board Chair

QIAGEN N.V. (NYSE: QGEN) today announced that its Supervisory Board has elected Stephen H. Rusckowski as Chairman following the Annual General Meeting of Shareholders (AGM) on June 26, 2025.

He succeeds Lawrence A. Rosen, who did not stand for re-election after serving for 12 years on the Supervisory Board. The Dutch Corporate Governance Code indicates that Directors of public companies should not serve more than 12 years for a company on their Supervisory Board.

At the AGM, where 80.4% of QIAGEN’s issued shares were represented, shareholders approved all proposed resolutions, including the initiation of an annual cash dividend and a new share repurchase authorization of up to $500 million.

Mr. Rusckowski joined the Supervisory Board in 2023 and has served as Chairman of the Nomination & Governance Committee and as a member of the Human Resources & Compensation Committee. He brings deep global healthcare and leadership experience, having previously served as Chairman, President and CEO of Quest Diagnostics and as CEO of Philips Healthcare.

Mr. Rusckowski said: “QIAGEN has built an outstanding portfolio of solutions trusted for their quality and scientific excellence. What continues to impress me is the clear vision that drives this company: a commitment to making improvements in life possible. I take on this role with deep respect for QIAGEN, its culture and its people, and with a clear recognition of the Supervisory Board’s responsibility to be a strong and engaged partner for shareholders and other stakeholders.”

Mr. Rosen stepped down after serving as Chairman since 2020 and serving as a member of the Supervisory Board since 2013. Under his leadership, QIAGEN underwent a period of focused strategic transformation and strengthened governance. Five new members have joined the Supervisory Board since 2020, enhancing its already strong international profile and deep expertise.

“It has been an extraordinary privilege to serve QIAGEN through a period of meaningful transformation and growth, and I believe QIAGEN has never been in a stronger position,” Mr. Rosen said. “I will very much enjoy watching the progress as the employees of QIAGEN do great things to help our customers advance science and improve healthcare for people around the world.”

Additionally, Prof. Dr. Elaine Mardis stepped down from the Supervisory Board after deciding not to stand for re-election. Prof. Dr. Mardis brought important scientific expertise to the Board since 2014, especially through her service on the Science & Technology and Human Resources & Compensation Committees.

Following the AGM, QIAGEN’s Supervisory Board now consists of eight members, reflecting the implementation of a plan announced in 2024 to return to a size consistent with historical levels and continuing to represent all the necessary expertise to support the future development of QIAGEN in a highly effective manner.

The AGM approved the re-appointment for one-year terms of the following Board members: Dr. Metin Colpan, Dr. Toralf Haag, Prof. Dr. Ross L. Levine, Mr. Bert van Meurs, Ms. Eva van Pelt, Dr. Eva Pisa, Ms. Elizabeth Tallett and Mr. Stephen H. Rusckowski.

Shareholders also approved the initiation of QIAGEN’s first-ever annual cash dividend - a milestone that reflects QIAGEN’s strong financial position and disciplined capital allocation strategy, which includes dividends in addition to organic investments, value-creating acquisitions and share repurchases.

The first dividend payment will be $0.25 per ordinary share, totaling approximately $54 million, with a record and ex-date of July 2, 2025, and payment date of July 10, 2025.

In addition, the AGM approved a new synthetic share repurchase authorization of up to $500 million, reinforcing QIAGEN’s commitment to returning capital to shareholders while preserving financial flexibility to invest in innovation and long-term growth.

You May Also Be Interested In

• Domino's Q2 2026 earnings call rescheduled to 11 a.m. ET after webcast issues
• QIAGEN touts Cyclospora detection tools amid U.S. outbreak
• Elastic earns AI Security distinction in AWS Security Competency